DMAAR — Stock Film
STOCK FILMSCENE 1/9DMAAR · $0.14
Stock Expert AI presents
DMAAR
Drugs Made In America Acquisition Corp. Rights
~3 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Drugs Made In America Acquisition Corp. Rights. A quick introduction.

On the stock market since 2026, it operates in the world of money and finance. It has 2 employees. Now — the numbers.

on the stock market since 2026
2 employees
$360.8M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, less than $1 stays as net profit.

This is an established company with proven profits.

What executives did with their own stock over the last 12 months:
12 buy4 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
37
weak

Clearly below the class average.

FINANCIAL STRENGTH
1
very weak

For a bank, strength is measured by capital buffers and reserves — not cash minus debt.

VALUATION
13
very weak

Clearly below the class average.

GROWTH
5
very weak

Clearly below the class average.

PRICE MOMENTUM
86
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Financial Strength: The capital buffer looks thin next to its class; less room to absorb a rough stretch.

Growth: Sales growth trails the sector average.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 37% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/1
Executives are buying their own stock

Over the last 12 months, company executives reported 12 buys and 4 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Trading under $1

The stock sits at $0.14. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

2
THE RISKS · 2/2
A wildly swinging price

This stock swings about 4.3 times as much as the market average. Big rallies — and big drops — can both happen fast.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, DMAAR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: DMAAR is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film